How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

The patient did not receive immunotherapy initially due to delayed insurance authorization. His performance status is poor, and his main toxicity from tepotinib was grade 3 edema.

Answer from: Medical Oncologist at Academic Institution

This is one of the more challenging situations I face in the clinic. Peripheral edema is the most notorious side effect of MET TKIs, with an insidious onset of 6-9 weeks after initiation of therapies like capmatinib or tepotinib [Sakamoto and Patil, PMID 36924573; Lin et al., PMID 40386723]. You hav...

Please select the option that best describes you:

How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

Related Questions